Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.

However, Connect Biopharma's phase 2 Seabreeze STAT Asthma trial's primary treatment-failure end point missed statistical significance.

Wechsler, of National Jewish Health discusses how oral STAT6 degraders like KT-621 could offer a mechanistically distinct treatment option.

Wechsler walks through verekitug's mechanism, VALIANT's design, key efficacy and safety findings, and what's next for TSLP-targeted asthma therapy.

Neal Bhatia, MD, weighs the newly approved Ameluz PDT regimen for sBCC against Mohs surgery, citing its 66% composite response rate.

Read 6 late-breaking updates from ERS Congress 2026 that clinicians managing respiratory disease should know.

The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.

The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.